Immuno-pharma company, AIM ImmunoTech (NYSE American: AIM) has published a new data analysis from a long-term Early Access Program studying the company’s drug Ampligen® (rintatolimod)…
Privately-held biotechnology company, Axial Therapeutics, is investigating the gut-brain connection as it advances a treatment for Autism Spectrum Disorder (ASD). The company’s lead product candidate,…
March 19, 2024
Anavex Advances Schizophrenia Drug in Phase 2 Study
Anavex Life Sciences (Nasdaq: AVXL) has screened the first patient in its Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia, ahead of…
BioNxt Solutions Inc. (OTCQB: BNXTF) has completed a comparative pharmacokinetic (PK) study of its oral dissolvable film (ODF) based proprietary Cladribine product for the treatment…
March 09, 2024
Industry Momentum Sets Strong Pace for Biotech IPOs
Biotech companies launching IPOs in the first quarter of 2024 have been largely met with enthusiasm and optimism from investors. The first two months of…
March 08, 2024
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton for Alzheimer’s, Parkinson’s Diseases
Late clinical-stage biopharmaceutical company, Athira Pharma, Inc. (Nasdaq: ATHA), has presented new clinical data highlighting the therapeutic potential of fosgonimeton at the AD/PD™ 2024 International…
Australian biotechnology company, Immuron Limited (Nasdaq: IMRN) has announced positive interim topline results from its study of Travelan® in preventing moderate to severe diarrhea following…
February 28, 2024
PRISM Rare Disease Spotlight: Capricor Therapeutics Advances Treatment for Duchenne Muscular Dystrophy
Rare disease company, Capricor Therapeutics (Nasdaq: CAPR), has been granted an in-person Type-B meeting with the FDA to discuss chemistry, manufacturing and controls (CMC) plans…
February 27, 2024
PRISM Rare Disease Spotlight: Voyager Therapeutics Selects Development Candidate for Friedreich’s Ataxia, Triggers $5M Milestone Payment
Voyager Therapeutics (Nasdaq: VYGR) has selected a lead development candidate in its Friedreich’s Ataxia (FA) program. The company expects the program to advance into first-in-human…
Shares in clinical-stage biopharmaceutical company Viking Therapeutics, Inc. (Nasdaq: VKTX) have surged more than 100% in intraday trading on Tuesday after the company announced it…
February 27, 2024
Tarsus Achieves Positive Topline Results in Lyme Disease Trial
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) has announced positive topline results from a Phase 2a trial evaluating TP-05 (lotilaner), a novel, investigational oral therapeutic for the…
February 21, 2024
Vaxxinity Advances Cholesterol Vaccine
A vaccine that could lower LDL cholesterol levels in the blood could soon be a reality for the nearly 94 million adults over the age…